BACKGROUND:Cysteinyl leukotrienes (CysLTs) are important mediators of asthma in children. Predictors of susceptibility to CysLT effects have not been developed. OBJECTIVES: To identify susceptibility markers to CysLT effects and montelukast response. METHODS:Twenty-seven schoolchildren were followed for 5 months with measurements of urinary leukotriene E4 (LTE(4)), cotinine, fractional exhaled nitric oxide (FENO), and monitoring of albuterol use. After a baseline run-in, children were randomized to receive daily montelukast or placebo without change in their current controller medications. RESULTS: At baseline, a significant (P = .003) positive association was observed between LTE(4) levels and albuterol use 2 days later. LTE(4)-relatedalbuterol usage (ie, change per interquartile increase in LTE(4)) declined significantly after montelukast treatment (12% decline; P = .0005 for relative difference between intervals) but not placebo (2% increase; P = .80). Declines in LTE(4)-related albuterol usage between intervals tended to be greater in girls (P = .01 for girls; P = .21 for boys; P = .07 for interaction) and were greater among children with higher cotinine levels (P = .01 for high cotinine group; P = .17 for low cotinine group; P = .04 for interaction). Children with high LTE(4) levels relative to FENO demonstrated significant (P = .05) declines in LTE(4)-related albuterol usage between intervals (P = .89 for low ratio group; P = .25 for interaction). CONCLUSION: Increased individual CysLT levels are associated with subsequent albuterol usage. CysLT-related albuterol usage and montelukast responsiveness are increased in children exposed to tobacco smoke and tend to be greater in girls than boys. Measurement of LTE(4) to FENO ratios may help predict susceptibility to montelukast.
RCT Entities:
BACKGROUND:Cysteinyl leukotrienes (CysLTs) are important mediators of asthma in children. Predictors of susceptibility to CysLT effects have not been developed. OBJECTIVES: To identify susceptibility markers to CysLT effects and montelukast response. METHODS: Twenty-seven schoolchildren were followed for 5 months with measurements of urinary leukotriene E4 (LTE(4)), cotinine, fractional exhaled nitric oxide (FENO), and monitoring of albuterol use. After a baseline run-in, children were randomized to receive daily montelukast or placebo without change in their current controller medications. RESULTS: At baseline, a significant (P = .003) positive association was observed between LTE(4) levels and albuterol use 2 days later. LTE(4)-related albuterol usage (ie, change per interquartile increase in LTE(4)) declined significantly after montelukast treatment (12% decline; P = .0005 for relative difference between intervals) but not placebo (2% increase; P = .80). Declines in LTE(4)-related albuterol usage between intervals tended to be greater in girls (P = .01 for girls; P = .21 for boys; P = .07 for interaction) and were greater among children with higher cotinine levels (P = .01 for high cotinine group; P = .17 for low cotinine group; P = .04 for interaction). Children with high LTE(4) levels relative to FENO demonstrated significant (P = .05) declines in LTE(4)-related albuterol usage between intervals (P = .89 for low ratio group; P = .25 for interaction). CONCLUSION: Increased individual CysLT levels are associated with subsequent albuterol usage. CysLT-related albuterol usage and montelukast responsiveness are increased in children exposed to tobacco smoke and tend to be greater in girls than boys. Measurement of LTE(4) to FENO ratios may help predict susceptibility to montelukast.
Authors: Jason E Lang; Allen J Dozor; Janet T Holbrook; Edward Mougey; Sankaran Krishnan; Shawn Sweeten; Robert A Wise; W Gerald Teague; Christine Y Wei; David Shade; John J Lima Journal: J Allergy Clin Immunol Pract Date: 2013-01-12
Authors: Nathan Rabinovitch; Nora J Graber; Vernon M Chinchilli; Christine A Sorkness; Robert S Zeiger; Robert C Strunk; Leonard B Bacharier; Fernando D Martinez; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2010-09 Impact factor: 10.793
Authors: Michael Armstrong; Andrew H Liu; Ronald Harbeck; Rick Reisdorph; Nathan Rabinovitch; Nichole Reisdorph Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2009-08-18 Impact factor: 3.205
Authors: Markus Braun; Doris Klingelhöfer; Gerhard M Oremek; David Quarcoo; David A Groneberg Journal: Int J Environ Res Public Health Date: 2020-05-05 Impact factor: 3.390